Author

Daniel Trotier

Observed names: Daniel C. Trotier, Daniel Clancy Trotier

Institution: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Observed institutions: University of Wisconsin–Madison, Eastern Virginia Medical School, Medical College of Wisconsin, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, UW Health University Hospital, University of Wisconsin Carbone Cancer Center, The Ohio State University

ORCID: 0009-0003-3997-5286

Observed ORCID: 0009-0003-3997-5286

OpenAlex ID: A5084019547

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

2025 · Taylor R. Brooks, Emily C. Zabor, et al. · Blood · 41

Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges

2024 · Giannis Mountzios, Jarushka Naidoo, et al. · American Society of Clinical Oncology Educational Book · 24

Review of recent advances in managing periocular skin malignancies

2024 · Daniel C. Trotier, Leslie Huang, et al. · Frontiers in Oncology · 16

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

2024 · Taylor R. Brooks, Emily C. Zabor, et al. · Blood · 15

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

2025 · Ajay Major, Diana Abbott, et al. · Blood · 1

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

2025 · Taylor Brooks, Agrima Mian, et al. · Blood · 1

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

2025 · XI Yang, Yasmin Karimi, et al. · Blood · 1

Evaluation of the Patient Global Impression of Symptom Severity (PGISS) Score as a Subjective and Objective Measure of Disease Activity in Chronic Rhinosinusitis

2025 · Subin Lim, Daniel Trotier, et al. · American Journal of Rhinology and Allergy · 1

Implementation of a clinical trial communication skills training workshop for oncology fellows: A mixed methods evaluation

2026 · Naomi D. Parker, Susan Eggly, et al. · PEC Innovation

Abstract 912: Non-Hodgkin’s lymphoma survival by neighborhood disinvestment and socioeconomic composition.

2026 · Jesse J. Plascak, Elizabeth Ghias, et al. · Cancer Research

The time toxicity of CAR-T cell therapy for non-Hodgkin's lymphoma

2025 · Daniel Trotier, Nadine Abdallah, et al. · Blood

Has Palliative Care and Hospice Utilization Changed for Patients with Relapsed/Refractory Large B-Cell Lymphoma in the Era of CAR-T?

2025 · Daniel Clancy Trotier, Manlu Liu, et al. · Transplantation and Cellular Therapy

805 SOX4 Drives Early Enteroendocrine Specification and Exit From the Intestinal Stem Cell State

2016 · Adam D. Gracz, Daniel C. Trotier, et al. · Gastroenterology

Works count: 13

Citation count: 100

H-index: 4

I10-index: 4